Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells

Over half of cutaneous melanoma tumors have BRAF V600E/K mutations. Acquired resistance to BRAF inhibitors (BRAFi) remains a major hurdle in attaining durable therapeutic responses. In this study we demonstrate that ~50–60% of melanoma cell lines with vemurafenib resistance acquired in vitro show ac...

Full description

Saved in:

Bibliographic Details
Published in:	Oncogene Vol. 39; no. 7; pp. 1466 - 1483
Main Authors:	Misek, S. A., Appleton, K. M., Dexheimer, T. S., Lisabeth, E. M., Lo, R. S., Larsen, S. D., Gallo, K. A., Neubig, R. R.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 13-02-2020 Nature Publishing Group
Subjects:	13/106 13/95 14/63 38 38/39 38/77 38/90 38/91 631/67/1059/2326 631/67/1813/1634 82/29 Adaptor Proteins, Signal Transducing - metabolism Apoptosis Cancer Care and treatment Cell activation Cell Biology Cell Dedifferentiation - drug effects Cell differentiation Cell Line, Tumor Cell lines Drug resistance Enzyme Activation - drug effects G proteins Gene expression Genes Genetic transcription Health aspects Human Genetics Humans Internal Medicine Kinases Learning algorithms Machine learning Medicine Medicine & Public Health Melanocytes - drug effects Melanocytes - pathology Melanoma Melanoma - pathology Oncology Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - antagonists & inhibitors Rho-associated kinase rho-Associated Kinases - metabolism RhoA protein Signal Transduction - drug effects Transcription Transcription Factors - metabolism Transcription, Genetic - drug effects Tumors Vemurafenib YAP-Signaling Proteins Yes-associated protein
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!